The document discusses population pharmacokinetic (PK) analysis. Population PK seeks to identify factors that cause variability in drug concentrations among patients and quantify their effects to help determine appropriate dosages. It describes common PK parameters, software used for PK analysis like NONMEM, and approaches for analyzing population PK data, including nonlinear mixed-effects modeling. An example population PK analysis is provided using simulated gentamicin concentration-time data from 30 patients to illustrate modeling the typical response, heterogeneity between individuals, and uncertainty in the model.
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Bayesian theory in population pharmacokinetics--
1) INTRODUCTION TO BAYESIAN THEORY
2)BAYESIAN PROBABILITY TO DOSING OF DRUGS
3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS:
therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes
Population pharmacokinetics is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Bayesian theory in population pharmacokinetics--
1) INTRODUCTION TO BAYESIAN THEORY
2)BAYESIAN PROBABILITY TO DOSING OF DRUGS
3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS:
therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes
Population pharmacokinetics is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest
Genetic polymorphism in drug transport and drug targets.pavithra vinayak
Genetic polymorphism in drug transport and targets.--pharmacogenetics
DRUG TRANSPORTER
Two types of transporter :
•ATP binding Cassette (ABC) – Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer.
•Solute Carrier (SLC) – Transport varieties of solute include both charged or uncharged
P-glycoprotein
• ATP binding cassette subfamily B member- 1 (ABCB 1)
• Multidrug resistance protein 1 (MDR1)
• Transport various molecules, including xenobiotic, across cell membrane
• Extensively distributed and expressed throughout the body
Mechanism of Pglycoprotein
Substrate bind to P-gp form the inner leaflet of the membrane
ATP binds at the inner side of the protein
ATP is hydrolyzed to produce ADP and energy
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
THIS SLIDE GIVES AN INSIGHT TO THE DIFFERENT METHODS THAT COULD BE USED FOR THE DOSAGE ADJUSTMENT IN PATIENTS WITH RENAL DISEASE.
RENAL FUNCTION OF THE PATIENT IS ASSESSED TO DETERMINE THE DOSAGE ADJUSTMENT
Bayesian theory was developed to improve forecast accuracy by combining subjective prediction with improvement from newly collected data.
Bayesian probability is used to improve forecasting in medicine.
Bayesian theory provides a method to weigh the prior information (e.g. physical diagnosis) and new information (e.g. results from laboratory tests) to estimate a new probability for predicting the disease.
Nomograms and tabulations in design of dosage regimens pavithra vinayak
Nomograms and tabulations in the design of dosage regimens --- NOMOGRAM IN UREMIC PATIENTS: NOMOGRAM FOR RELATIONSHIP BETWEEN CREATININE CLEARANCE AND ELIMINATION RATE CONSTANT FOR FOUR DRUGS clinical pharmacokinetics and therapeutic drug monitoring ---fifth PharmD notes
Genetic polymorphism in drug transport and drug targets.pavithra vinayak
Genetic polymorphism in drug transport and targets.--pharmacogenetics
DRUG TRANSPORTER
Two types of transporter :
•ATP binding Cassette (ABC) – Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer.
•Solute Carrier (SLC) – Transport varieties of solute include both charged or uncharged
P-glycoprotein
• ATP binding cassette subfamily B member- 1 (ABCB 1)
• Multidrug resistance protein 1 (MDR1)
• Transport various molecules, including xenobiotic, across cell membrane
• Extensively distributed and expressed throughout the body
Mechanism of Pglycoprotein
Substrate bind to P-gp form the inner leaflet of the membrane
ATP binds at the inner side of the protein
ATP is hydrolyzed to produce ADP and energy
various measures for the measurement of outcome such as incidence prevalence and other drug us measures are briefly discussed here with suitable examples and equations
THIS SLIDE GIVES AN INSIGHT TO THE DIFFERENT METHODS THAT COULD BE USED FOR THE DOSAGE ADJUSTMENT IN PATIENTS WITH RENAL DISEASE.
RENAL FUNCTION OF THE PATIENT IS ASSESSED TO DETERMINE THE DOSAGE ADJUSTMENT
Bayesian theory was developed to improve forecast accuracy by combining subjective prediction with improvement from newly collected data.
Bayesian probability is used to improve forecasting in medicine.
Bayesian theory provides a method to weigh the prior information (e.g. physical diagnosis) and new information (e.g. results from laboratory tests) to estimate a new probability for predicting the disease.
Nomograms and tabulations in design of dosage regimens pavithra vinayak
Nomograms and tabulations in the design of dosage regimens --- NOMOGRAM IN UREMIC PATIENTS: NOMOGRAM FOR RELATIONSHIP BETWEEN CREATININE CLEARANCE AND ELIMINATION RATE CONSTANT FOR FOUR DRUGS clinical pharmacokinetics and therapeutic drug monitoring ---fifth PharmD notes
The mobile space is exploding and affiliates need to avoid mistakes and move quickly to generate revenue. Discuss practical case studies and learn from our real-life client examples.
Experience level: Beginner, Intermediate, Advanced
Target audience: Affiliate/Publisher, Merchant/Advertiser
Niche/vertical: Mobile
Jeff Stevens, Director of Sales, DirectTrack (Twitter @jstevnz )
If you’re responsible for creating diverse, scalable automated tests but don’t have the time, budget, or a skilled-enough team to create yet another custom test automation framework, then you need to know about Robot Framework!
In this webinar, Bryan Lamb (Founder, RobotFrameworkTutorial.com) and Chris Broesamle (Solutions Engineer, Sauce Labs) will reveal how you can use this powerful, free, open source, generic framework to create continuous automated regression tests for web, batch, API, or database testing. With the simplicity of Robot Framework, in conjunction with Sauce Labs, you can improve your test coverage and time to delivery of your applications.
Management 315: International Management, Professor In Hyeock Lee
Loyola University Chicago Spring 2013
This case study analyzes Honda's overall performance as a multinational enterprise using the company's revenue data, 4 distances, firm specific advantages, country specific advantages, foreign direct investment, and much more.
Sham Hassan Chikkegowda, CS Engineer, and Timothee Maret, Senior Developer, of Adobe provide a review of using Security Assertion Markup Language (SAML) with your Experience Manager deployments. SAML is an XML-based, open-standard data format for exchanging authentication and authorization data between parties, in particular, between an identity provider and a service provider. SAML is a product of the OASIS Security Services Technical Committee. To watch the session on demand at http://bit.ly/AEMGems72016 or the MP4 version http://bit.ly/AEMGem72016
In this presentation i have tried to explain in brief about nomograms and their applications, the general approach to individualise doage regimen by using pharmacokinetic data
The presentation concisely describes the different pharmacokinetic parameters and basics of compartment modelling. It will help undergraduate students to understand the basic concepts of Biopharmaceutics.
This presentation will give the students a basic knowledge about the pharmacokinetics of durgs. It will help them clear the basics before digging deep into the topic.
INTRODUCTION TO PHARMACOKINETIC MODELS, ONE COMPARTMENT OPEN MODEL IV BOLUS, IV INFUSION, EXTRAVASCULAR ADMINISTRATION, WAGNER NELSON METHOD, METHOD OF RESIDUALS
Clinical Trial Simulation to Evaluate the Pharmacokinetics of an Abuse-Deterr...Loan Pham
A CTS was performed to estimate the sample size and optimal plasma sampling times that sufficiently characterize the PK parameters (CL, Vd) from a single dose of an abuse-deterrent (AD) opioid in pediatric subjects.
I have tried to provide an outline regarding the general antivirals available in our country..and discussed regarding MOA,indications and Therapeutic uses.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
2. PHARMACOKINETIC DATA
intended to define the time course of drug and major
metabolite concentrations in plasma and other biological
fluids in order to obtain information on absorption,
distribution, metabolism, and elimination.
Importance??
Pharmacokinetically guided dose escalation (PGDE) studies
Dose fixing in Phase II and subsequent studies.
To adapt drug dosage to the individual patient (therapeutic
drug monitoring)
3. Relevant PK parameters
Total clearance (CL),
Fraction of dose excreted unchanged in urine (fe),
Volume of distribution at steady state (Vss),
Volume of distribution during the terminal phase (VZ),
Blood/plasma concentration ratio,
Terminal half-life (t1/2 Z),
Fraction of unbound drug in plasma (fu),
Bioavailable fraction of dose (F), if applicable, and
Absorption rate constant (ka),
4. Designing a dosage regimen..
Following parameters should be known as well:
Area under the plasma concentration time curve(AUC),
Maximum concentration (Cmax),
Minimum concentration (Cmin) after repeated dosing,
and Time of Cmax (tmax).
In addition, the effective and toxic concentrations should
be assessed
5. Population PK: from 1972 to 1977
Population pharmacokinetics is the study of the sources
and correlates of variability in drug concentrations among
individuals who are the target patient population
receiving clinically relevant doses of a drug of interest.
Pop PK seeks to identify the measurable pathophysiologic
factors that cause changes in the dose-concentration
relationship and the extent of these changes so that, if
such changes are associated with clinically significant shifts
in the therapeutic index, dosage can be appropriately
modified.
6. Population pharmacokinetics incl:
Assessment of global variability of the plasma drug
concentration profile in a patient population.
Allocation of this variability to pharmacokinetic
parameters (e.g. variability of clearance, bioavailability,
etc).
Explanation of variability by identifying factors of
demographic, pathophysiological, environmental, or
concomitant drug-related origin that may influence the
pharmacokinetic parameters.
Quantitative estimation of the magnitude of the
unexplained variability in the patient population.
7. What does PK software do?
Fitting drug concentration-versus-time data to a series of
pharmacokinetic models, and choosing the one that best
describes the data statistically.
Fitting data into a pharmacokinetic or pharmacodynamic
model defined by the user
Simulation
Experimental design
Clinical pharmacokinetic applications
Computer programs for teaching
8.
The application of population analysis methods to
therapeutic problems has led to on-going methodological
and software development which in further has
established more complex applications.
Commonly used softwares used for analysis of PK data:
NONEM (NONlinear Mixed Effects Modeling) * -developed by
S.L.Beal and L.B. Sheiner
MK MODEL – developed by National Institutes Of Health
Support PROPHET system
NPEM 2 ( Non Parametric Expectation Maximization),
version 3- well adapted for Pop Pk
11. Other softwares incl.
USCPACK PC PROGRAMS*
Consists of various Pk programs
Clinical programs incl. related routines in which past therapy
data for individual patients are entered into files along with
parameter and dose predication programs for various drugs
like:
Amikacin(amik)
Gentamicin(Gent)
Netilmicin(Net)
Tobramycin (Tob)
Bayesian General Modeling (MB)
Least Squared General Modeling
12. Population analysis
Synonym: repeated measures modeling, non linear mixed
effects modeling, non linear hierarchical modeling.
Pop PK analysis refer to a set of statistical techniques that
can be used to learn about the average response in a
population as well as the variability in response that arises
from different sources.
Population analysis is the application of a model to
describe data that arise from more than one individual
13. Approaches for analyzing Pop PK data
Standard two - stage approach
refers to fitting a pharmacokinetic model to the data of
each individual
Afterwards summary statistics are computed for the total
collection of individual parameter estimates
Using this approach, the inter individual variance tends to
be overestimated.
it is not applicable when the individual data are too sparse
for individual model fits.
14. Contd..
Nonlinear Mixed-Effects Modelling Approach
With this type of modelling not only pharmacokinetic
parameters but also inter-individual variance parameters
are estimated.
The parameters are population means, shift parameters,
and inter-individual and residual variance parameters
A population pharmacokinetic data analysis should include
relevant covariates, e.g. age, weight, gender, creatinine
clearance, co-medication, and concomitant diseases
Quantitative relationships between covariates and
pharmacokinetic parameters often help predict individual
PK before any individual data have been obtained.
15. Considering an example….
PK model for a gentamicin-like drug that incorporates the
central elements relevant to a population analysis.
This drug displays one compartment model characteristics
Vd =20 L and clearance (4 L Hr -1)
dose admn by IV bolus.
We used this PK model to simulate plasma concentration–time
data for 30 patients who received a single intravenous bolus
dose of 420 mg (6 mg /kg for a 70 kg individual),where each
patient provided seven blood samples at times 0.25, 0.5, 1, 2, 4, 8
and 12 h following dosing.
17. A population analysis was then conducted on the
simulation 'dataset’.
A population model for our data will consist of three
elements:
(1) A model for the typical response – this is the response
for a typical (average) patient,
(2) a model for heterogeneity and
(3) a model for uncertainty.
18. Model for typical response
This is sometimes also called a structural model. For
pharmacokinetics this would be a compartmental model
that describes the plasma drug concentration over time
(see Figure 2A).
The pharmacokinetic model that describes our
gentamicin- like drug at a specific time (t) is:
19. A) The observed concentration–time data overlaid with the median predicted
concentration from the PK model.
(B) Observed concentration–time data overlaid with the median and 2.5th and
97.5th percentiles of the predicted concentrations from the PK model
20. Model of heterogeneity
We use the term heterogeneity in population analysis to
describe the variability between individuals. This is also
termed Between Subject Variability (BSV) or InterIndividual Variability (IIV).
This involves two distinct models:
a model developed to describe predictable reasons why
individuals are different.
a model developed to quantify the remaining source of
random variability
Figure 2B encompass the observed plasma concentration
data of our PK example.
21. CLCR as an abbreviation for creatinine clearance
CLNR as an abbreviation for non-renal clearance
EXPLANATION:
22. FIGURE 3
Individual estimates of systemic drug
CL vs. creatinine clearance.
The line is the regression line and
the intercept represents non-renal
clearance
and the slope represents the
fraction of drug cleared unchanged
by the kidneys.
The vertical difference of any
individual from the regression line
represents the difference of that
individual from the population
average and is given by c
(Equation3)
23. Predicted concentrations from
the PK model that does not
include the covariate CLCR (solid
line).
Predicted concentrations from a
PK model that includes the
covariate CLCR as a covariate on
CL (dashed lines).
Includingthe covariate CLCR in
the model reduces the
unexplained variability in the
model predictions and hence
improves the reliability of the
model predictions
24. Model for Uncertainty
This model describes why the 1st and 2nd models do not
match the observations exactly.
Uncertainty is also called residual error. It is assumed that
uncertainty arises from (at least) four sources:
(i) process error – where the dose or timing of dose or timing of
blood samples are not conducted at the times that they are
recorded,
(ii) measurement error – where the response (e.g. concentration)
is not measured exactly due to assay error,
(iii) model misspecification – where the models we propose in
Equations 1–3 are in reality too simple and
(iv) moment to moment variability within a patient.
25.
The final component to add to our analysis must account
for the uncertainty in our model predictions. We need to
assume (not essential but) that the uncertainty is entirely
random and due to error; so by incorporating,
This error represents the (residual) difference of the
model prediction from the data